CDRH Task Force Stirs Debate About FDA's Comparative-Effectiveness Role
This article was originally published in The Gray Sheet
Executive Summary
FDA stakeholders debated Feb. 9 whether it is appropriate for the agency to compare the effectiveness of new devices to the status quo as part of its pre-market reviews